Walleye Capital
VIR icon

Walleye Capital’s Vir Biotechnology VIR Stock Holding History

Walleye Capital’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.24M Sell
514,251
-151,333
-23% -$1.44M 0.02% 800
2026
Q1 		$5.96M Buy
665,584
+409,459
+160% +$3.26M 0.02% 697
2025
Q4 		$1.54M Buy
256,125
+117,295
+84% +$698K ﹤0.01% 2073
2025
Q3 		$793K Sell
138,830
-45,100
-25% -$231K ﹤0.01% 2276
2025
Q2 		$927K Sell
183,930
-67,036
-27% -$359K ﹤0.01% 2112
2025
Q1 		$1.63M Sell
250,966
-183,494
-42% -$1.63M 0.01% 1581
2024
Q4 		$3.19M Buy
434,460
+410,684
+1,727% +$3.24M 0.01% 1383
2024
Q3 		$178K Buy
+23,776
New +$207K ﹤0.01% 4086
2024
Q2 		– Sell
-172,656
Closed -$1.75M – 6043
2024
Q1 		$1.75M Sell
172,656
-11,168
-6% -$114K ﹤0.01% 2087
2023
Q4 		$1.85M Sell
183,824
-394,711
-68% -$3.61M ﹤0.01% 1852
2023
Q3 		$5.42M Sell
578,535
-284,845
-33% -$4.06M 0.01% 978
2023
Q2 		$21.2M Buy
+863,380
New +$21.7M 0.08% 152
2022
Q1 		– Sell
-5,100
Closed -$214K – 2618
2021
Q4 		$214K Buy
+5,100
New +$200K 0.01% 1432

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Walleye Capital's VIR Position: Q2 2026 in Review

Walleye Capital reduced its Vir Biotechnology (VIR) stake by 23% in Q2 2026, selling an estimated $1.44M and leaving 514,251 shares worth $5.24M. The position accounts for 0.02% of the portfolio, ranked #800.

Walleye Capital first reported a position in VIR in Q4 2021 and has held it in 13 quarters since. The position peaked at $21.2M in Q2 2023. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Walleye Capital held 514,251 shares of Vir Biotechnology worth $5.24M as of Q2 2026.
  • Walleye Capital sold 151,333 Vir Biotechnology shares in Q2 2026, an estimated $1.44M.
  • Vir Biotechnology made up 0.02% of Walleye Capital's portfolio in Q2 2026, its #800 holding.
  • Walleye Capital first reported a position in Vir Biotechnology in Q4 2021 and has held it in 13 quarters since.
  • Walleye Capital's Vir Biotechnology position peaked at $21.2M in Q2 2023.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.